Cholangiocarcinoma Excellence Forum

Cholangiocarcinoma

Excellence Forum

Vivek Subbiah, MD, Sarah Cannon Research Institute

Videos

Management of Adverse Events Associated With FGFR Inhibitors

12/12/2023

Featuring Vivek Subbiah, MD

Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.

Vivek Subbiah, MD, discusses the...

12/12/2023

Oncology

Quiz

Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases

11/27/2023

Do you know which outcome was less frequent among patients with cholangiocarcinoma with extrahepatic metastases who received liver-directed radiotherapy? Take our quick quiz to find out!

Do you know which outcome was...

11/27/2023

Oncology

Quiz

Real-World Experience With Gemcitabine-Cisplatin Plus Durvalumab For Biliary Tract Cancer

11/27/2023

Do you know the results of the real-world analysis of the efficacy of gemcitabine and cisplatin plus durvalumab among patients with advanced biliary tract cancer? Take our quick quiz to find out!

Do you know the results of the...

11/27/2023

Oncology

Andrea Casadei-Gardini, MD, San Raffaele Research Hospital

Videos

Real-World Efficacy and Safety of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer

09/22/2023

Featuring Andrea Casadei-Gardini, MD

Featuring Andrea Casadei-Gardini, MD ...

A real-world analysis of durvalumab plus gemcitabine-cisplatin confirmed the results seen in previous clinical trials, supporting the use of this combination in clinical practice.

A real-world analysis of...

09/22/2023

Oncology

Eugene Koay, MD, PhD, MD Anderson Cancer Center

Videos

Definitive Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases

09/14/2023

Featuring Eugene Koay, MD, PhD

Featuring Eugene Koay, MD, PhD ...

Eugene Koay, MD, PhD, discusses a study which found liver radiotherapy for patients with intrahepatic cholangiocarcinoma and extrahepatic metastases was associated with a longer overall survival, compared with chemotherapy alone.

Eugene Koay, MD, PhD, discusses...

09/14/2023

Oncology

Monica Niger, MD, National Cancer Institute - MIlan

Videos

Clinical Relevance of BRAF Alterations in Biliary Tract Cancers

08/22/2023

Featuring Monica Niger, MD

At the 2023 World Congress on Gastrointestinal Cancers, Monica Niger, MD, discusses the clinical relevance and actionability of BRAF alterations among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/22/2023

Oncology

Leony Antoun, MD, Gustave Roussy Cancer Campus

Videos

Effect of Molecular Profiling on Survival Among Patients With Biliary Tract Cancers

08/09/2023

Featuring Leony Antoun, MD

At the 2023 World Congress on Gastrointestinal Cancers, Leony Antoun, MD, discusses the impact of molecular profiling on survival among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/09/2023

Oncology

Quiz

Dual IDH1/2 Inhibitor Response Rate in Cholangiocarcinoma

07/20/2023

What was the response rate among patients with locally advanced or metastatic IDH1/2 mutant cholangiocarcina who received the dual IDH1/2 inhibitor LY3410738 in combination with cisplatin-gemcitabine?

What was the response rate among...

07/20/2023

Oncology

James Harding, MD, Memorial Sloan Kettering Cancer Center

Videos

Novel Dual IDH-Inhibitor Plus Chemotherapy Showed Promising Efficacy, Safety for Patients With Advanced IDH-Mutant Cholangiocarcinoma

07/12/2023

Featuring James Harding, MD

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, the IDH1/2-inhibitor LY3410738 showed promising efficacy and safety in combination with chemotherapy for patients with locally advanced or metastatic...

According to a study presented...

07/12/2023

Oncology

Quiz

Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma

06/15/2023

True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.

True or False: Patients with...

06/15/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology